AMONDYS 45

(casimersen) 100 mg/2 mL injection

DOSING & ADMINISTRATION GUIDE

SareptaDMD.com/AMONDYS45

INDICATIONS AND USAGE

AMONDYS 45 is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the *DMD* gene that is amenable to exon 45 skipping. This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with AMONDYS 45. Continued approval for this indication may be contingent upon verification of a clinical benefit in confirmatory trials.

Nicholas, AGE 12
DELETION OF EXON 44

Please see the Indication and Important Safety Information on pages 2, 3, 6, 7, 13, and the full Prescribing Information for AMONDYS 45 (casimersen).

AMONDYS 45
(casimersen) 100 mg/2 mL injection

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS: AMONDYS 45 is contraindicated in patients with a known serious hypersensitivity to casimersen or any of the inactive ingredients in AMONDYS 45. Instances of hypersensitivity including angioedema and anaphylaxis have occurred.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions: Hypersensitivity reactions, including angioedema and anaphylaxis, have occurred in patients who were treated with AMONDYS 45. If a hypersensitivity reaction occurs, institute appropriate medical treatment, and consider slowing the infusion, interrupting, or discontinuing the AMONDYS 45 infusion and monitor until the condition resolves. AMONDYS 45 is contraindicated in patients with known serious hypersensitivity to casimersen or to any of the inactive ingredients in AMONDYS 45.

Kidney Toxicity: Kidney toxicity was observed in animals who received casimersen. Although kidney toxicity was not observed in the clinical studies with AMONDYS 45, kidney toxicity, including potentially fatal glomerulonephritis, has been observed after administration of some antisense oligonucleotides. Kidney function should be monitored in patients taking AMONDYS 45. Because of the effect of reduced skeletal muscle mass on creatinine measurements, creatinine may not be a reliable measure of kidney function in DMD patients. Serum cystatin C, urine dipstick, and urine protein-to-creatinine ratio should be measured before starting AMONDYS 45. Consider also measuring glomerular filtration rate using an exogenous filtration marker before starting AMONDYS 45. During treatment, monitor urine dipstick every month, and serum cystatin C and urine protein-to-creatinine ratio (UPCR) every three months. Only urine expected to be free of excreted AMONDYS 45 should be used for monitoring of urine protein. Urine obtained on the day of AMONDYS 45 infusion prior to the infusion, or urine obtained at least 48 hours after the most recent infusion, may be used. Alternatively, use a laboratory test that does not use the reagent pyrogallol red, as this reagent has the potential to cross react with any AMONDYS 45 that is excreted in the urine and thus lead to a false positive result for urine protein.

If a persistent increase in serum cystatin C or proteinuria is detected, refer to a pediatric nephrologist for further evaluation.

ADVERSE REACTIONS: Adverse reactions occurring in at least 20% of patients treated with AMONDYS 45 and at least 5% more frequently than in the placebo group were (AMONDYS 45, placebo): upper respiratory infections (65%, 55%), cough (33%, 26%), pyrexia (33%, 23%), headache (32%, 19%), arthralgia (21%, 10%), and oropharyngeal pain (21%, 7%).

Other adverse reactions that occurred in at least 10% of patients treated with AMONDYS 45 and at least 5% more frequently than in the placebo group were: ear pain, nausea, ear infection, post-traumatic pain, and dizziness and light-headedness.

Other adverse events may occur.

To report **SUSPECTED ADVERSE REACTIONS,** contact Sarepta Therapeutics, Inc. at **1-888-SAREPTA** (1-888-727-3782) or FDA at **1-800-FDA-1088** or **www.fda.gov/medwatch**.

Before administration, please see the full Prescribing Information for AMONDYS 45 (casimersen).

Colin, AGE 11
DELETIONS OF EXONS 12-44

Please see the Indication and Important Safety Information on pages 2, 3, 6, 7, 13, and the full Prescribing Information for AMONDYS 45 (casimersen).

AMONDYS 45
(casimersen) 100 mg/2 mL injection

TABLE OF CONTENTS

Please see the Indication and Important Safety Information on pages 2, 3, 6, 7, 13, and the full Prescribing Information for AMONDYS 45 (casimersen).

AMONDYS 45 (casimersen) 100 mg/2 mL injection

INTRODUCTION[1]

Patient eligibility: AMONDYS 45 should only be administered to patients who have a confirmed mutation of the *DMD* gene that is amenable to skipping exon 45.

Contraindications: AMONDYS 45 is contraindicated in patients with a known serious hypersensitivity to casimersen or any of the inactive ingredients in AMONDYS 45. Instances of hypersensitivity, including angioedema and anaphylaxis, have occurred in patients receiving AMONDYS 45.

Safety monitoring: Serum cystatin C, urine dipstick, and urine protein-to-creatinine ratio should be measured before starting AMONDYS 45. Consider measurement of glomerular filtration rate prior to initiation of AMONDYS 45. Monitoring for kidney toxicity during treatment is recommended. Obtain the urine samples prior to infusion of AMONDYS 45 or at least 48 hours after the most recent infusion.

Dosing: The recommended dose of AMONDYS 45 is 30 mg/kg administered once weekly as a 35- to 60-minute intravenous (IV) infusion via an in-line 0.2 micron filter. If a dose of AMONDYS 45 is missed, it may be administered as soon as possible after the scheduled dose.

Infusion site care: Application of a topical anesthetic cream to the infusion site prior to administration of AMONDYS 45 may be considered.

Hypersensitivity reactions: Advise patients and/or caregivers that hypersensitivity reactions, including angioedema and anaphylaxis, have occurred in patients who were treated with AMONDYS 45. Instruct them to seek immediate medical care should they experience signs and symptoms of hypersensitivity.

Kidney toxicity: Inform patients that nephrotoxicity has occurred with drugs similar to AMONDYS 45. Advise patients of the importance of monitoring for kidney toxicity by their healthcare providers during treatment with AMONDYS 45.

Infusion-related reactions: Advise patients and/or caregivers that infusion-related reactions, including rash, headache, cough, abdominal pain (including upper abdominal pain), and vomiting occurred within 24 hours from the start of an infusion of AMONDYS 45.

How AMONDYS 45 is supplied: AMONDYS 45 injection is supplied in single-dose vials containing 100 mg/2 mL (50 mg/mL) casimersen. The solution is a clear to slightly opalescent, colorless liquid, and may contain trace amounts of small, white to off-white amorphous particles.

Storage: Store AMONDYS 45 at 2 °C to 8 °C (36 °F to 46 °F). Do not freeze. Store AMONDYS 45 in the original carton until ready for use to protect from light.

IMPORTANT SAFETY INFORMATION

Adverse Reactions: Adverse reactions occurring in at least 20% of patients treated with AMONDYS 45 and at least 5% more frequently than in the placebo group were (AMONDYS 45, placebo): upper respiratory infections (65%, 55%), cough (33%, 26%), pyrexia (33%, 23%), headache (32%, 19%), arthralgia (21%, 10%), and oropharyngeal pain (21%, 7%).

Please see the Indication and Important Safety Information on pages 2, 3, 6, 7, 13, and the full Prescribing Information for AMONDYS 45 (casimersen).

BEFORE THE INFUSION

PROPER STORAGE AND HANDLING OF AMONDYS 45[1]

Once you receive AMONDYS 45 at your facility, be sure to store it according to proper procedures:

Store AMONDYS 45 at 2 °C to 8 °C (36 °F to 46 °F)



Protect from light and store in the original carton until ready for use



Do not freeze

Other adverse reactions that occurred in at least 10% of patients treated with AMONDYS 45 and at least 5% more frequently than in the placebo group were: ear pain, nausea, ear infection, post-traumatic pain, and dizziness and light-headedness.

AMONDYS 45 DOSING CALCULATIONS[1]

To calculate the dose of AMONDYS 45 you will need to:

STEP 1 Calculate the patient dose in mg:
Patient weight (kg) x 30 mg/kg = total dose in mg of AMONDYS 45

STEP 2 Calculate the volume in mL:

Total mg of AMONDYS 45 needed ÷ **50 mg/mL** = **Total volume in mL** of AMONDYS 45 needed

STEP 3 Calculate the number of single-dose vials the patient needs:
Total mL needed ÷ 2 = # of 2 mL vials

DOSING CALCULATION EXAMPLE BASED ON 33.5 KG PATIENT

STEP 1 Calculate the dose in mg:
33.5 kg x 30 mg/kg = 1,005 mg

STEP 2 Calculate the volume in mL:
1,005 mg ÷ 50 mg/mL = 20.1 mL

STEP 3 Calculate the number of single-dose vials:
20.1 mL = 11 (eleven) 2-mL vials

NECESSARY SUPPLIES[1]

To infuse AMONDYS 45 you will need:

AMONDYS 45
2-mL single-dose vials containing
100 mg casimersen



0.9% sodium chloride injection, USP,
(normal saline solution) infusion bag
(volume of 100-150 mL)



0.2 micron filter

A syringe fitted with a 21-gauge
or smaller bore non-coring needle

Please see the Indication and Important Safety Information on pages 2, 3, 6, 7, 13, and the full Prescribing Information for AMONDYS 45 (casimersen).

AMONDYS 45
(casimersen) 100 mg/2 mL injection

PREPARING AMONDYS 45 USING ASEPTIC TECHNIQUE[1,2]

PREPARE AMONDYS 45 ACCORDING TO THESE STEPS

STEP 1

Complete the dosing calculation.
See page 8 of this brochure for information on how to complete the dosing calculation.

STEP 2

AMONDYS 45 is administered once weekly as a 35- to 60-minute intravenous (IV) infusion via an in-line 0.2 micron filter.

Application of a topical anesthetic cream to the infusion site prior to administration of AMONDYS 45 may be considered.

STEP 3

Assess the patient's IV or port for patency prior to removing any vials from the refrigerator. If IV access is adequate, remove the appropriate number of vials from the refrigerator and allow them to warm to room temperature. Do not microwave vials.

STEP 4

Once at room temperature, mix the contents of each vial by gently inverting 2 or 3 times. Do not shake. Visually inspect each vial of AMONDYS 45. AMONDYS 45 is a clear to slightly opalescent, colorless liquid, and may contain trace amounts of small, white to off-white amorphous particles. Do not use if the solution is cloudy, discolored, or contains extraneous particulate matter other than trace amounts of small, white to off-white amorphous particles. If there is an issue with the solution, please report the issue to Sarepta at 1-888-SAREPTA (1-888-727-3782).

STEP 5

With a syringe fitted with a 21-gauge or smaller bore non-coring needle, withdraw the calculated volume of AMONDYS 45 from the appropriate number of vials.

STEP 6

Dilute the withdrawn AMONDYS 45 in 0.9% sodium chloride injection, USP, to make a total volume of 100 to 150 mL. Before diluting AMONDYS 45, withdraw excess saline from the bag, if needed. Gently invert 2 to 3 times to mix. Do not shake. Visually inspect the diluted solution. Do not use if the solution is cloudy, discolored, or contains extraneous particulate matter other than trace amounts of small, white to off-white amorphous particles.

AMONDYS 45 contains no preservatives and should be administered immediately after dilution. Complete infusion of diluted AMONDYS 45 within 4 hours of dilution. If immediate use is not possible, the diluted product may be stored for up to 24 hours at 2 °C to 8 °C (36 °F to 46 °F). Do not freeze. Discard unused AMONDYS 45.

INFUSING AMONDYS 45[1,3]

ADMINISTER AMONDYS 45 ACCORDING TO THESE STEPS

STEP 7

- Flush the patient's intravenous access line with 0.9% sodium chloride injection, USP, prior to infusion.
- Infuse the diluted AMONDYS 45 over 35 to 60 minutes via an in-line 0.2 micron filter. Do not mix other medications with AMONDYS 45 or infuse other medications concomitantly via the same intravenous access with AMONDYS 45.
- If a hypersensitivity reaction occurs, consider slowing the infusion, interrupting, or discontinuing the AMONDYS 45 therapy.
- After completion of the infusion, flush the intravenous access line with 0.9% sodium chloride injection, USP, to allow the entire dose, including the contents of the intravenous access line, to be administered.
- In cases where AMONDYS 45 is administered into a venous access port, after administration of the drug and flushing with normal saline, the port may be flushed with heparin prior to de-access.

ADDITIONAL IMPORTANT INFORMATION

When administering AMONDYS 45 to patients with implanted infusion devices, access the device following the manufacturer's instructions for use to minimize the potential for infection.

Please see the Indication and Important Safety Information on pages 2, 3, 6, 7, 13, and the full Prescribing Information for AMONDYS 45 (casimersen).

AMONDYS 45 (casimersen) 100 mg/2 mL injection

AFTER THE INFUSION[1]

STEP 8 Once you have completed the infusion, discard any unused product.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS: AMONDYS 45 is contraindicated in patients with a known serious hypersensitivity to casimersen or any of the inactive ingredients in AMONDYS 45. Instances of hypersensitivity including angioedema and anaphylaxis have occurred.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions: Hypersensitivity reactions, including angioedema and anaphylaxis, have occurred in patients who were treated with AMONDYS 45. If a hypersensitivity reaction occurs, institute appropriate medical treatment, and consider slowing the infusion, interrupting, or discontinuing the AMONDYS 45 infusion and monitor until the condition resolves. AMONDYS 45 is contraindicated in patients with known serious hypersensitivity to casimersen or to any of the inactive ingredients in AMONDYS 45.

Kidney Toxicity: Kidney toxicity was observed in animals who received casimersen. Although kidney toxicity was not observed in the clinical studies with AMONDYS 45, kidney toxicity, including potentially fatal glomerulonephritis, has been observed after administration of some antisense oligonucleotides. Kidney function should be monitored in patients taking AMONDYS 45. Because of the effect of reduced skeletal muscle mass on creatinine measurements, creatinine may not be a reliable measure of kidney function in DMD patients. Serum cystatin C, urine dipstick, and urine protein-to-creatinine ratio should be measured before starting AMONDYS 45. Consider also measuring glomerular filtration rate using an exogenous filtration marker before starting AMONDYS 45. During treatment, monitor urine dipstick every month, and serum cystatin C and urine protein-to-creatinine ratio (UPCR) every three months. Only urine expected to be free of excreted AMONDYS 45 should be used for monitoring of urine protein. Urine obtained on the day of AMONDYS 45 infusion prior to the infusion, or urine obtained at least 48 hours after the most recent infusion, may be used. Alternatively, use a laboratory test that does not use the reagent pyrogallol red, as this reagent has the potential to cross react with any AMONDYS 45 that is excreted in the urine and thus lead to a false positive result for urine protein.

If a persistent increase in serum cystatin C or proteinuria is detected, refer to a pediatric nephrologist for further evaluation.

ADVERSE REACTIONS: Adverse reactions occurring in at least 20% of patients treated with AMONDYS 45 and at least 5% more frequently than in the placebo group were (AMONDYS 45, placebo): upper respiratory infections (65%, 55%), cough (33%, 26%), pyrexia (33%, 23%), headache (32%, 19%), arthralgia (21%, 10%), and oropharyngeal pain (21%, 7%).

Other adverse reactions that occurred in at least 10% of patients treated with AMONDYS 45 and at least 5% more frequently than in the placebo group were: ear pain, nausea, ear infection, post-traumatic pain, and dizziness and light-headedness.

Other adverse events may occur.

To report **SUSPECTED ADVERSE REACTIONS,** contact Sarepta Therapeutics, Inc. at **1-888-SAREPTA** (1-888-727-3782) or FDA at **1-800-FDA-1088** or **www.fda.gov/medwatch**.

Before administration, please see the full Prescribing Information for AMONDYS 45 (casimersen).

SAREPTASSIST

Support, By Your Patients' Side

SareptAssist is a personalized support program here to help your patients on their treatment journey.

We can help:

- Understand the requirements for treatment
- Consider financial assistance options
- Explore your insurance benefits
- Prepare for treatment
- Find helpful resources
- Provide ongoing education and support

Get your patients started in 3 steps:

1. **Visit SareptAssist.com** and download the Enrollment Form (available in English and Spanish)
2. **Fill out the Enrollment Form** and fax it to SareptAssist at 1-800-621-5203
3. **A dedicated SareptAssist Case Manager** will contact your patient soon

Call 1-888-SAREPTA
(1-888-727-3782)

Case Managers are available Monday through Friday, 8:30 am – 6:30 pm ET

Spanish-speaking Case Managers and interpreters for other languages are available

References: 1. AMONDYS 45 [package insert]. Cambridge, MA: Sarepta Therapeutics, Inc. 2024. **2.** Infusion Nurses Society. Infusion Therapy Standards of Practice 2016, Online edition. *Journal of Infusion Nursing*. Accessed on July 17, 2024. http://ins.tizrapublisher.com/hai13r/ **3.** Data on file. Sarepta Therapeutics, Inc.

SAREPTA THERAPEUTICS